JAGXJaguar Health, Inc.
- AccessWire
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance ...
- AccessWire
Jaguar Health Reports Second Quarter 2026 Financials
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results ...
- AccessWire
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. today announced ...
- AccessWire
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized ...
- AccessWire
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance ...
- AccessWire
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support for rare IF diseases, including MVID SAN FRANCISCO, CA / ACCESS Newswire / ...
- AccessWire
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of study, which ...
- AccessWire
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseasesReminder: Two crofelemer presentations in pediatric intestinal failure patients with ...
- AccessWire
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results SAN FRANCISCO, CA / ACCESS Newswire / June 23, 2026 / ...
- AccessWire
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal ...
- AccessWire
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2026 / Jaguar Health, Inc. today ...
- AccessWire
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Click here to register for eventTo access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click hereReminder: Two crofelemer presentations ...
- AccessWire
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar Health, Inc. ...
- AccessWire
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being ...
- AccessWire
Jaguar Health Compliant with Nasdaq Bid Price Rule
JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. today announced that on May 26, 2026, the ...
- AccessWire
Jaguar Health Reports First Quarter 2026 Financials
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1Company continues its focus on crofelemer ...
- AccessWire
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners ConferenceCompany plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the ...
- AccessWire
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive ...
- AccessWire
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. today provided an update on the status of the Company's listing on The Nasdaq Stock Market . On ...
- AccessWire
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Pediatric patients with Intestinal Failure due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support , could benefit ...
- AccessWire
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydration, and bowel ...
- AccessWire
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. today announced topline results ...
- AccessWire
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / April 27, 2026 / ...
- AccessWire
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Intestinal Failure occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease and/or short bowel syndrome Jaguar has received orphan drug designations for MVID & SBS ...
- AccessWire
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. today announced the voting results of the Company's Special Meeting of Stockholders held on April 20, ...